Novo Nordisk A/S (NVO)

Market Cap	184.75B -38.6%
Revenue (ttm)	50.57B +8.1%
Net Income	18.81B +16.6%
EPS	4.23 +16.8%
Shares Out	4.44B
PE Ratio	9.82
Forward PE	13.25
Dividend	$1.29 (3.00%)
Ex-Dividend Date	Mar 30, 2026

Volume	14,540,200
Open	41.67
Previous Close	42.19
Day's Range	41.66 - 44.03
52-Week Range	35.12 - 81.44
Beta	0.35
Analysts	Buy
Price Target	47.00 (+9.63%)
Earnings Date	May 6, 2026

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 69,505
• Stock Exchange: NYSE
• Ticker Symbol: NVO
• Website: https://www.novonordisk.com

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Analyst Summary

According to 14 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $47.0, which is an increase of 9.63% from the latest price.

Price Target

$47.0

(9.63% upside)

Analyst Consensus: Buy